Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor Malignancies
**Background:** Certain governmental agencies, patient advocacy organizations, and pharmaceutical manufacturers have implemented programs to assist patients in overcoming barriers to accessing healthcare. Recently, such programs have expanded their services, helping both uninsured and insured patien...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2016-10-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/9846 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860382824923136 |
|---|---|
| author | Lindsay Parker Alissa Shaul Brian Murphy Zeba M. Khan |
| author_facet | Lindsay Parker Alissa Shaul Brian Murphy Zeba M. Khan |
| author_sort | Lindsay Parker |
| collection | DOAJ |
| description | **Background:** Certain governmental agencies, patient advocacy organizations, and pharmaceutical manufacturers have implemented programs to assist patients in overcoming barriers to accessing healthcare. Recently, such programs have expanded their services, helping both uninsured and insured patients to navigate the complex healthcare system, and assisting with increasing out-of pocket costs and copays for the drugs.
**Objective:** To better understand the effect of patient support programs on access to therapy for solid tumor malignancies, this study evaluated service use, case outcomes, and patient characteristics from a manufacturer-sponsored program in the United States.
**Methods:** Sociodemographic characteristics, services use rates, and outcomes by case and insurance type were evaluated at the patient- and case-level in a random sample of patients prescribed nab-paclitaxel for solid tumor malignancies who enrolled in the Celgene Patient Support (CPS) program (April 2011–November 2013).
**Results:** This analysis included 4566 patients (8134 cases); most patients were female (64.7%), aged <65 years (59.2%), in the South (53.9%), and treated in community settings (87.9%). Patients were primarily insured by Medicare (38.5%) or commercial plans (37.3%), or were uninsured (16.6%). Following benefits investigations for new patients entering the program (98.5%), CPS provided support to obtain free medicine (29.4%), appeal denial of coverage (15.0%), receive commercial co-payment assistance (8.1%), or obtain prior payer authorization (1.3%). Nab-paclitaxel was provided at no cost in 89.4% of cases where patients sought financial support; payer reimbursement was obtained in 63.2% of reimbursement appeals. Of commercially-insured patients who required assistance with co-payments and met financial criteria, 93.3% received a mean of $597 in co-payment support.
**Conclusion:** The CPS program was successful in gaining access to therapy. Healthcare providers and both insured or uninsured patients accessed CPS for prior authorization/precertification, appeals support, and financial support through the Free Medication Program and the Commercial Co-Pay program. |
| format | Article |
| id | doaj-art-e1cf3d3e311148808764d0420612df15 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2016-10-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-e1cf3d3e311148808764d0420612df152025-02-10T16:12:45ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362016-10-0131Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor MalignanciesLindsay ParkerAlissa ShaulBrian MurphyZeba M. Khan**Background:** Certain governmental agencies, patient advocacy organizations, and pharmaceutical manufacturers have implemented programs to assist patients in overcoming barriers to accessing healthcare. Recently, such programs have expanded their services, helping both uninsured and insured patients to navigate the complex healthcare system, and assisting with increasing out-of pocket costs and copays for the drugs. **Objective:** To better understand the effect of patient support programs on access to therapy for solid tumor malignancies, this study evaluated service use, case outcomes, and patient characteristics from a manufacturer-sponsored program in the United States. **Methods:** Sociodemographic characteristics, services use rates, and outcomes by case and insurance type were evaluated at the patient- and case-level in a random sample of patients prescribed nab-paclitaxel for solid tumor malignancies who enrolled in the Celgene Patient Support (CPS) program (April 2011–November 2013). **Results:** This analysis included 4566 patients (8134 cases); most patients were female (64.7%), aged <65 years (59.2%), in the South (53.9%), and treated in community settings (87.9%). Patients were primarily insured by Medicare (38.5%) or commercial plans (37.3%), or were uninsured (16.6%). Following benefits investigations for new patients entering the program (98.5%), CPS provided support to obtain free medicine (29.4%), appeal denial of coverage (15.0%), receive commercial co-payment assistance (8.1%), or obtain prior payer authorization (1.3%). Nab-paclitaxel was provided at no cost in 89.4% of cases where patients sought financial support; payer reimbursement was obtained in 63.2% of reimbursement appeals. Of commercially-insured patients who required assistance with co-payments and met financial criteria, 93.3% received a mean of $597 in co-payment support. **Conclusion:** The CPS program was successful in gaining access to therapy. Healthcare providers and both insured or uninsured patients accessed CPS for prior authorization/precertification, appeals support, and financial support through the Free Medication Program and the Commercial Co-Pay program.https://doi.org/10.36469/9846 |
| spellingShingle | Lindsay Parker Alissa Shaul Brian Murphy Zeba M. Khan Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor Malignancies Journal of Health Economics and Outcomes Research |
| title | Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor Malignancies |
| title_full | Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor Malignancies |
| title_fullStr | Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor Malignancies |
| title_full_unstemmed | Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor Malignancies |
| title_short | Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor Malignancies |
| title_sort | effectiveness of a patient support program in supporting access to therapy for solid tumor malignancies |
| url | https://doi.org/10.36469/9846 |
| work_keys_str_mv | AT lindsayparker effectivenessofapatientsupportprograminsupportingaccesstotherapyforsolidtumormalignancies AT alissashaul effectivenessofapatientsupportprograminsupportingaccesstotherapyforsolidtumormalignancies AT brianmurphy effectivenessofapatientsupportprograminsupportingaccesstotherapyforsolidtumormalignancies AT zebamkhan effectivenessofapatientsupportprograminsupportingaccesstotherapyforsolidtumormalignancies |